Compare Stocks

3 / 10
Try these comparisons:

Stock Comparison

INDV vs RBBN vs AVPT

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
INDV
Indivior Pharmaceuticals Inc

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$4.94B
5Y Perf.+890.0%
RBBN
Ribbon Communications Inc.

Telecommunications Services

Communication ServicesNASDAQ • US
Market Cap$472M
5Y Perf.-38.9%
AVPT
AvePoint, Inc.

Software - Infrastructure

TechnologyNASDAQ • US
Market Cap$2.23B
5Y Perf.+5.4%

INDV vs RBBN vs AVPT — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
INDV logoINDV
RBBN logoRBBN
AVPT logoAVPT
IndustryDrug Manufacturers - Specialty & GenericTelecommunications ServicesSoftware - Infrastructure
Market Cap$4.94B$472M$2.23B
Revenue (TTM)$1.29B$826M$444M
Net Income (TTM)$251M$31M$47M
Gross Margin83.1%48.7%73.7%
Operating Margin33.3%-0.7%9.6%
Forward P/E12.7x20.7x27.7x
Total Debt$351M$405M$10M
Cash & Equiv.$195M$96M$481M

INDV vs RBBN vs AVPTLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

INDV
RBBN
AVPT
StockMay 20May 26Return
Indivior Pharmaceut… (INDV)100990.0+890.0%
Ribbon Communicatio… (RBBN)10061.1-38.9%
AvePoint, Inc. (AVPT)100105.4+5.4%

Price return only. Dividends and distributions are not included.

Quick Verdict: INDV vs RBBN vs AVPT

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: INDV leads in 5 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. AvePoint, Inc. is the stronger pick specifically for growth and revenue expansion. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
INDV
Indivior Pharmaceuticals Inc
The Income Pick

INDV carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.

  • Dividend streak 1 yrs, beta 0.68
  • 281.7% 10Y total return vs AVPT's 5.5%
  • Lower P/E (12.7x vs 27.7x)
Best for: income & stability and long-term compounding
RBBN
Ribbon Communications Inc.
The Secondary Option

RBBN plays a supporting role in this comparison — it may shine differently against other peers.

Best for: communication services exposure
AVPT
AvePoint, Inc.
The Growth Play

AVPT is the clearest fit if your priority is growth exposure and sleep-well-at-night.

  • Rev growth 26.9%, EPS growth 193.8%, 3Y rev CAGR 21.8%
  • Lower volatility, beta 1.06, Low D/E 2.1%, current ratio 2.28x
  • Beta 1.06, current ratio 2.28x
Best for: growth exposure and sleep-well-at-night
See the full category breakdown
CategoryWinnerWhy
GrowthAVPT logoAVPT26.9% revenue growth vs RBBN's 1.3%
ValueINDV logoINDVLower P/E (12.7x vs 27.7x)
Quality / MarginsINDV logoINDV19.4% margin vs RBBN's 3.8%
Stability / SafetyINDV logoINDVBeta 0.68 vs RBBN's 1.49
DividendsTieNone of these 3 stocks pay a meaningful dividend
Momentum (1Y)INDV logoINDV+244.9% vs AVPT's -40.0%
Efficiency (ROA)INDV logoINDV19.1% ROA vs RBBN's 2.7%, ROIC 342.7% vs 2.1%

INDV vs RBBN vs AVPT — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

INDVIndivior Pharmaceuticals Inc
FY 2025
Reportable Segment
100.0%$1.2B
RBBNRibbon Communications Inc.
FY 2025
Cloud and Edge
60.6%$511M
IP Optical Networks
39.4%$333M
AVPTAvePoint, Inc.
FY 2024
SaaS
76.1%$319M
Termed License and Support
10.7%$45M
Service
10.5%$44M
Maintenance
2.7%$11M

INDV vs RBBN vs AVPT — Financial Metrics

Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLINDVLAGGINGAVPT

Income & Cash Flow (Last 12 Months)

Evenly matched — INDV and AVPT each lead in 3 of 6 comparable metrics.

INDV is the larger business by revenue, generating $1.3B annually — 2.9x AVPT's $444M. INDV is the more profitable business, keeping 19.4% of every revenue dollar as net income compared to RBBN's 3.8%. On growth, AVPT holds the edge at +26.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricINDV logoINDVIndivior Pharmace…RBBN logoRBBNRibbon Communicat…AVPT logoAVPTAvePoint, Inc.
RevenueTrailing 12 months$1.3B$826M$444M
EBITDAEarnings before interest/tax$447M$40M$47M
Net IncomeAfter-tax profit$251M$31M$47M
Free Cash FlowCash after capex-$185M$17M$105M
Gross MarginGross profit ÷ Revenue+83.1%+48.7%+73.7%
Operating MarginEBIT ÷ Revenue+33.3%-0.7%+9.6%
Net MarginNet income ÷ Revenue+19.4%+3.8%+10.5%
FCF MarginFCF ÷ Revenue-14.3%+2.0%+23.6%
Rev. Growth (YoY)Latest quarter vs prior year+19.2%-10.3%+26.0%
EPS Growth (YoY)Latest quarter vs prior year+81.6%-33.3%+3.6%
Evenly matched — INDV and AVPT each lead in 3 of 6 comparable metrics.

Valuation Metrics

RBBN leads this category, winning 5 of 6 comparable metrics.

At 12.2x trailing earnings, RBBN trades at a 82% valuation discount to AVPT's 68.8x P/E. On an enterprise value basis, RBBN's 9.6x EV/EBITDA is more attractive than AVPT's 44.8x.

MetricINDV logoINDVIndivior Pharmace…RBBN logoRBBNRibbon Communicat…AVPT logoAVPTAvePoint, Inc.
Market CapShares × price$4.9B$472M$2.2B
Enterprise ValueMkt cap + debt − cash$5.1B$781M$1.8B
Trailing P/EPrice ÷ TTM EPS24.15x12.23x68.80x
Forward P/EPrice ÷ next-FY EPS est.12.65x20.69x27.75x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple17.88x9.57x44.79x
Price / SalesMarket cap ÷ Revenue3.99x0.56x5.31x
Price / BookPrice ÷ Book value/share1.08x4.94x
Price / FCFMarket cap ÷ FCF18.13x27.32x
RBBN leads this category, winning 5 of 6 comparable metrics.

Profitability & Efficiency

AVPT leads this category, winning 6 of 9 comparable metrics.

AVPT delivers a 10.2% return on equity — every $100 of shareholder capital generates $10 in annual profit, vs $8 for RBBN. AVPT carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to RBBN's 0.90x. On the Piotroski fundamental quality scale (0–9), AVPT scores 6/9 vs INDV's 4/9, reflecting solid financial health.

MetricINDV logoINDVIndivior Pharmace…RBBN logoRBBNRibbon Communicat…AVPT logoAVPTAvePoint, Inc.
ROE (TTM)Return on equity+7.9%+10.2%
ROA (TTM)Return on assets+19.1%+2.7%+6.3%
ROICReturn on invested capital+3.4%+2.1%+11.4%
ROCEReturn on capital employed+79.1%+2.4%+8.1%
Piotroski ScoreFundamental quality 0–9456
Debt / EquityFinancial leverage0.90x0.02x
Net DebtTotal debt minus cash$156M$309M-$471M
Cash & Equiv.Liquid assets$195M$96M$481M
Total DebtShort + long-term debt$351M$405M$10M
Interest CoverageEBIT ÷ Interest expense10.88x-0.02x
AVPT leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

INDV leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in INDV five years ago would be worth $36,837 today (with dividends reinvested), compared to $3,899 for RBBN. Over the past 12 months, INDV leads with a +244.9% total return vs AVPT's -40.0%. The 3-year compound annual growth rate (CAGR) favors AVPT at 32.6% vs RBBN's 0.6% — a key indicator of consistent wealth creation.

MetricINDV logoINDVIndivior Pharmace…RBBN logoRBBNRibbon Communicat…AVPT logoAVPTAvePoint, Inc.
YTD ReturnYear-to-date+10.8%-7.2%-21.9%
1-Year ReturnPast 12 months+244.9%-11.8%-40.0%
3-Year ReturnCumulative with dividends+97.0%+1.9%+133.0%
5-Year ReturnCumulative with dividends+268.4%-61.0%+1.7%
10-Year ReturnCumulative with dividends+281.7%-68.2%+5.5%
CAGR (3Y)Annualised 3-year return+25.4%+0.6%+32.6%
INDV leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

INDV leads this category, winning 2 of 2 comparable metrics.

INDV is the less volatile stock with a 0.68 beta — it tends to amplify market swings less than RBBN's 1.49 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. INDV currently trades 96.6% from its 52-week high vs AVPT's 51.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricINDV logoINDVIndivior Pharmace…RBBN logoRBBNRibbon Communicat…AVPT logoAVPTAvePoint, Inc.
Beta (5Y)Sensitivity to S&P 5000.68x1.49x1.06x
52-Week HighHighest price in past year$41.00$4.29$20.25
52-Week LowLowest price in past year$10.63$1.80$8.83
% of 52W HighCurrent price vs 52-week peak+96.6%+62.7%+51.0%
RSI (14)Momentum oscillator 0–10079.654.354.1
Avg Volume (50D)Average daily shares traded2.6M879K1.6M
INDV leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: INDV as "Buy", RBBN as "Buy", AVPT as "Buy". Consensus price targets imply 69.6% upside for AVPT (target: $18) vs 12.8% for INDV (target: $45).

MetricINDV logoINDVIndivior Pharmace…RBBN logoRBBNRibbon Communicat…AVPT logoAVPTAvePoint, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyBuy
Price TargetConsensus 12-month target$44.67$3.50$17.50
# AnalystsCovering analysts3812
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises1
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap+0.2%+1.9%+2.2%
Insufficient data to determine a leader in this category.
Key Takeaway

INDV leads in 2 of 6 categories (Total Returns, Risk & Volatility). RBBN leads in 1 (Valuation Metrics). 1 tied.

Best OverallIndivior Pharmaceuticals Inc (INDV)Leads 2 of 6 categories
Loading custom metrics...

INDV vs RBBN vs AVPT: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is INDV or RBBN or AVPT a better buy right now?

For growth investors, AvePoint, Inc.

(AVPT) is the stronger pick with 26. 9% revenue growth year-over-year, versus 1. 3% for Ribbon Communications Inc. (RBBN). Ribbon Communications Inc. (RBBN) offers the better valuation at 12. 2x trailing P/E (20. 7x forward), making it the more compelling value choice. Analysts rate Indivior Pharmaceuticals Inc (INDV) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — INDV or RBBN or AVPT?

On trailing P/E, Ribbon Communications Inc.

(RBBN) is the cheapest at 12. 2x versus AvePoint, Inc. at 68. 8x. On forward P/E, Indivior Pharmaceuticals Inc is actually cheaper at 12. 7x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — INDV or RBBN or AVPT?

Over the past 5 years, Indivior Pharmaceuticals Inc (INDV) delivered a total return of +268.

4%, compared to -61. 0% for Ribbon Communications Inc. (RBBN). Over 10 years, the gap is even starker: INDV returned +281. 7% versus RBBN's -68. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — INDV or RBBN or AVPT?

By beta (market sensitivity over 5 years), Indivior Pharmaceuticals Inc (INDV) is the lower-risk stock at 0.

68β versus Ribbon Communications Inc. 's 1. 49β — meaning RBBN is approximately 120% more volatile than INDV relative to the S&P 500. On balance sheet safety, AvePoint, Inc. (AVPT) carries a lower debt/equity ratio of 2% versus 90% for Ribbon Communications Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — INDV or RBBN or AVPT?

By revenue growth (latest reported year), AvePoint, Inc.

(AVPT) is pulling ahead at 26. 9% versus 1. 3% for Ribbon Communications Inc. (RBBN). On earnings-per-share growth, the picture is similar: Indivior Pharmaceuticals Inc grew EPS 108. 3% year-over-year, compared to 171. 0% for Ribbon Communications Inc.. Over a 3-year CAGR, AVPT leads at 21. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — INDV or RBBN or AVPT?

Indivior Pharmaceuticals Inc (INDV) is the more profitable company, earning 16.

9% net margin versus 4. 7% for Ribbon Communications Inc. — meaning it keeps 16. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INDV leads at 21. 4% versus 2. 4% for RBBN. At the gross margin level — before operating expenses — INDV leads at 80. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is INDV or RBBN or AVPT more undervalued right now?

On forward earnings alone, Indivior Pharmaceuticals Inc (INDV) trades at 12.

7x forward P/E versus 27. 7x for AvePoint, Inc. — 15. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AVPT: 69. 6% to $17. 50.

08

Which pays a better dividend — INDV or RBBN or AVPT?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is INDV or RBBN or AVPT better for a retirement portfolio?

For long-horizon retirement investors, Indivior Pharmaceuticals Inc (INDV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

68), +281. 7% 10Y return). Both have compounded well over 10 years (INDV: +281. 7%, RBBN: -68. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between INDV and RBBN and AVPT?

These companies operate in different sectors (INDV (Healthcare) and RBBN (Communication Services) and AVPT (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: INDV is a small-cap quality compounder stock; RBBN is a small-cap deep-value stock; AVPT is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

INDV

High-Growth Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 9%
  • Net Margin > 11%
Run This Screen
Stocks Like

RBBN

Quality Business

  • Sector: Communication Services
  • Market Cap > $100B
  • Gross Margin > 29%
Run This Screen
Stocks Like

AVPT

High-Growth Compounder

  • Sector: Technology
  • Market Cap > $100B
  • Revenue Growth > 12%
  • Net Margin > 6%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform INDV and RBBN and AVPT on the metrics below

Revenue Growth>
%
(INDV: 19.2% · RBBN: -10.3%)
Net Margin>
%
(INDV: 19.4% · RBBN: 3.8%)
P/E Ratio<
x
(INDV: 24.1x · RBBN: 12.2x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.